Safety Study of SGN-CD48A in Patients With Multiple Myeloma

What is the purpose of this trial?

This study will test the safety and activity of SGN-CD48A given every 3 weeks to patients with multiple myeloma.

Seattle Genetics, Inc.

Start Date: 01/31/2018

End Date: 10/09/2020

Last Updated: 02/22/2018

Study HIC#: 2000021962